Answers are grounded in this paper and cite their sources.
Fifty-four adults with acute leukemia resistant to other therapies received treatment with Daunorubicin and L-asparaginase. Seventeen (31%) achieved complete remission. The complete remission rate was higher among the 31 patients receiving simultaneous therapy than among the 23 patients receiving sequential therapy (42% vs. 17%). Patients with acute lymphocytic leukemia had a higher remission rate than patients with acute myelogenous leukemia (38% vs. 20%). The median duration of complete remission was only 12 weeks, and the median duration of survival for responders was 30 weeks.
No takes yet. Share an insight, caveat, or question.
Bodey et al. (1974) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: